Karuna Therapeutics: Getting Sold Short (NASDAQ:KRTX)

CIPhotos Karuna Therapeutics (NASDAQ:KRTX) is on the verge or releasing a novel product to the market that will eschew dopamine modulation in favor of a more sophisticated action to treat psychosis related to Alzheimer’s and schizophrenia, according to our discussions with physicians and other experts in the field. Soon to be the first of its…

Read More

Karuna’s Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) (NASDAQ:KRTX)

wildpixel Introduction Karuna Therapeutics (NASDAQ:KRTX) develops innovative treatments for psychiatric and neurological disorders. Their investigational drug, KarXT, targets schizophrenia and Alzheimer’s-related psychosis with a unique mechanism, differing from dopaminergic or serotonergic pathways, offering a potential new treatment option. In my previous analysis of Karuna Therapeutics, I highlighted the potential of their antipsychotic drug, KarXT, to…

Read More